| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We previously developed an oncolytic adenovirus, OBP-301, in which the hTERT gene promoter drives the expression of the E1A and E1B genes. A phase I clinical trial of OBP-301 was conducted in the United States on patients with advanced solid tumors, and a phase II clinical trial is being conducted in our hospital on patients with advanced esophageal cancer. In this study, we revealed the cytopathic activity of OBP-301 in bone and soft tissue sarcoma cells. Moreover, OBP-301 enhanced chemosensitivity to doxorubicin and cisplatin in human osteosarcoma cells. The antitumor effect of OBP-301 was remarkable on human osteosarcoma orthotopic xenograft model; however, bone destruction could not be prevented by OBP-301 monotherapy. Combination treatment with OBP-301 and zoledronic acid showed a synergistic antitumor effect, and prevented bone destruction. Our data indicates that OBP-301 is a promising antitumor reagent for the treatment of bone and soft tissue sarcomas
|
